Last update 01 Nov 2024

Shanghai Langsheng Biotechnology Co., Ltd.

Private Company|
2020|
Shanghai Shi, China

Overview

Basic Info

Introduction
Shanghai Innostellar Biotherapeutics Co.,Ltd. is a high-tech enterprise specializing in the research, development, production and sales of biopharmaceuticals. The company adheres to the concept of "pioneering, innovative and excellent" and has always been committed to the development of safe, efficient and stable biopharmaceutical products.

Tags

Eye Diseases
Congenital Disorders
Other Diseases
AAV based gene therapy

Disease domain score
A glimpse into the focused therapeutic areas
no Data
No Data
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Top 5 Drug TypeCount
AAV based gene therapy2
Top 5 TargetCount
Capsid(Capsid protein)1
RPE65(Retinoid isomerohydrolase)1

Related

2
Drugs associated with Shanghai Langsheng Biotechnology Co., Ltd.
LX101 (Innostellar)
Target
RPE65
Mechanism
RPE65 gene transference
Active Org.
Shanghai Langsheng Biotechnology Co., Ltd. [+1]
Originator Org.
Shanghai Langsheng Biotechnology Co., Ltd.
Active Indication
Biallelic RPE65 mutation associated retinal dystrophy [+2]
Inactive Indication-
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
WO2024153075
Patent Mining
Target
Capsid
Mechanism-
Active Org.
Shanghai Langsheng Biotechnology Co., Ltd.
Originator Org.
Shanghai Langsheng Biotechnology Co., Ltd.
Active Indication
Eye Diseases
Inactive Indication-
Drug Highest PhaseDiscovery
First Approval Ctry. / Loc.-
First Approval Date-
7
Clinical Trials associated with Shanghai Langsheng Biotechnology Co., Ltd.
NCT06196840 / RecruitingPhase 2
A Phase 2, Randomized Controlled, Open-Label Study to Establish the Safety and Efficacy of LX102 in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)
NCT06212297 / RecruitingPhase 1/2
A Clinical Trial to Evaluate the Safety and Efficacy of Subretinal Re-Administration of LX101 to the Contralateral Eye in Subjects With Biallelic RPE65 Mutation-associated Inherited Retinal Dystrophy
NCT06198413 / RecruitingPhase 1
A Dose-Escalation Study of LX102 Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD)
100 Clinical Results associated with Shanghai Langsheng Biotechnology Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Shanghai Langsheng Biotechnology Co., Ltd.
Login to view more data
100 Deals associated with Shanghai Langsheng Biotechnology Co., Ltd.
Login to view more data
100 Translational Medicine associated with Shanghai Langsheng Biotechnology Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
1
1
Phase 3 Clinical
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
LX101 (Innostellar)
 ( RPE65 )		Biallelic RPE65 mutation associated retinal dystrophy
More
Phase 3
WO2024153075
 ( Capsid )		Eye Diseases
More
Discovery
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free